Chemical Structure : AZD 5069
CAS No.: 878385-84-3
货号: PC-60618Not For Human Use, Lab Use Only.
AZD 5069 (AZD5069) is a potent, selective, slowly reversible and orally bioavailable CXCR2 antagonist that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.1.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | ¥880 | In stock | |
10 mg | ¥1380 | In stock | |
25 mg | ¥2280 | In stock | |
50 mg | ¥3880 | In stock | |
100 mg | Get quote |
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
AZD 5069 (AZD5069) is a potent, selective, slowly reversible and orally bioavailable CXCR2 antagonist that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.1.
AZD5069 weakly inhibits CXCL8 binding to CXCR1 with pIC50<7, and no affinity for CCR2 and CCR5.
AZD5069 inhibits neutrophil chemotaxis with pA2 of 9.6, and adhesion molecule expression of 6.9, in response to CXCL1.
AZD5069 demonstrates potential activity in acute LPS-induced lung inflammation models.
分子量 | 476.51 | |
分子式 | C18H22F2N4O5S2 | |
外观性状 | Solid | |
储存条件 |
|
|
Solubility |
10 mM in DMSO |
|
Chemical Name/SMILES |
N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide |
1. Nicholls DJ, et al. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
2. Jurcevic S, et al. Br J Clin Pharmacol. 2015 Dec;80(6):1324-36.
3. Kirsten AM, et al. Pulm Pharmacol Ther. 2015 Apr;31:36-41.
4. Walters I, et la. Bioorg Med Chem Lett. 2008 Jan 15;18(2):798-803.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright